checkAd

Santhera Reports Interim Results on Convertible Bond Exchange Offer - Seite 2

Nachrichtenquelle: globenewswire
20.04.2021, 07:00  |  178   |   |   

Voting on bondholders' resolution continues
In parallel to conducting the Exchange Offer, Santhera continues to seek and obtain additional consents to the restructuring of the 2017/22 Bonds it had proposed to the bondholders’ meeting of March 8, 2021.

Santhera still requires further votes in order to reach the necessary two thirds majority. If a two thirds majority is achieved, the bondholders' resolution would, subject to court approval, become binding on all Bondholders, and the Exchange Offer would not be completed.

Bondholders may still vote on resolution and accept Exchange Offer
The amendments proposed to the bondholders’ meeting and the terms offered in the Exchange Offer are economically the same, mutatis mutandis. Hence Santhera encourages bondholders to submit their consent, if not already done, and simultaneously to accept the Exchange Offer.

Bondholders may both and simultaneously

(1)    vote on the bondholder’s resolution (if they have held the bonds since March 5, 2021, or earlier, and if they have not already voted), by filling out and submitting the forms that are published on the Santhera website under www.santhera.com/investors-and-media/investor-toolbox/share-bondholder-meetings, and

(2)    accept the Exchange Offer during the additional acceptance period (if they have not already done so) by instructing their custody bank accordingly.

These two decisions are completely independent from each other. A vote for the bondholders' resolution does not constitute an acceptance of the Exchange Offer, and acceptance of the Exchange Offer does not constitute a vote for the restructuring proposed to the bondholders' meeting.

Bondholders requiring assistance or additional information on the procedures are invited to contact Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, 4133 Pratteln (email: daniela.glatz@santhera.com; phone: +41 61 906 89 50).

Stifel Nicolaus Europe Limited is serving as sole financial advisor to the Company.

Related documents

Notice of a Repurchase Offer (Exchange of CHF 60,000,000 Senior Unsecured Convertible Bonds due 2022): https://www.santhera.com/investors-and-media/investor-toolbox/bond-exc ...

Preliminary Issuance and Listing Prospectus Regarding the New Bonds: https://www.santhera.com/investors-and-media/investor-toolbox/bond-exc ...

Forms to cast bondholder votes are available here.

Seite 2 von 5
Santhera Pharmaceuticals Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Santhera Reports Interim Results on Convertible Bond Exchange Offer - Seite 2 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, April 20, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that so far an aggregate principal value of around …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel